84(top 1%)
papers
1.8K(top 1%)
citations
18(top 2%)
h-index
42(top 1%)
g-index
89
all documents
2.1K
doc citations
567
citing journals

Top Articles

#TitleJournalYearCitations
1Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology2018388
2Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer PatientsClinical Cancer Research2018357
3Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 studyCancer Cell202199
4Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III StudyJournal of Clinical Oncology202297
5Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJournal of Thoracic Oncology202085
6Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1Genome Medicine202081
7Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with ChemotherapyClinical Cancer Research202179
8Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 TrialJournal of Thoracic Oncology202172
9Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trialNature Medicine202165
10Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trialAnnals of Oncology201464
11The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissuesBMC Cancer201859
12MicroRNA 543 suppresses breast cancer cell proliferation, blocks cell cycle and induces cell apoptosis via direct targeting of ERK/MAPKOncoTargets and Therapy201749
13Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancerInvestigational New Drugs201842
14Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patientsCancer Biology and Medicine201936
15A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study GroupLeukemia202035
16The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trialTranslational Lung Cancer Research201927
17Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective StudyClinical Lung Cancer202023
18Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world populationLung Cancer202023
19Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical studyCancer Communications202222
20Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line ChemotherapyAmerican Journal of Clinical Oncology: Cancer Clinical Trials201921
21<p>Frequency, clinical features and differential response to therapy of concurrent <em>ALK/EGFR</em> alterations in Chinese lung cancer patients</p>Drug Design, Development and Therapy201918
22Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter studyTranslational Lung Cancer Research202018
23The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective studyCancer Immunology, Immunotherapy202218
24Irinotecan plus S‐1 versus S‐1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open‐labeled phase 3 trialCancer Communications201917
25Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancersLung Cancer202017
26Targeting ALK Rearrangements in NSCLC: Current State of the ArtFrontiers in Oncology202215
27Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breastScientific Reports202112
28HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial202011
29Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case reportAnnals of Translational Medicine202011
30Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment FailureJAMA Network Open202011
31Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancerAnnals of Translational Medicine202211
32p63 expression is a prognostic factor in colorectal cancerInternational Journal of Biological Markers201210
33Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLCBMC Medicine202110
34D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study ResultsJournal of Thoracic Oncology202310
35Interleukin-13 +2044 G/A and +1923C/T polymorphisms are associated with asthma susceptibility in AsiansMedicine (United States)20179
36Hepatic veno-occlusive disease related to Gynura segetumMedicine (United States)20189
37LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trialAnnals of Oncology20229
38Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER ‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patientsCancer Medicine20228
39<p>The Multifunction Of miR-218-5p-Cx43 Axis In Breast Cancer</p>OncoTargets and Therapy20197
40A prognostic index for nasal‐type early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter studyAmerican Journal of Hematology20197
41Screening of important lncRNAs associated with the prognosis of lung adenocarcinoma, based on integrated bioinformatics analysisMolecular Medicine Reports20197
42Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.Journal of Clinical Oncology20217
43Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.Journal of Clinical Oncology20217
44Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 TrialJTO Clinical and Research Reports20227
45Efficacy and safety of recombinant human lymphotoxin‐α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open‐label, controlled, phase 2b trialCancer20176
46Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutationCancer Chemotherapy and Pharmacology20186
47Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patientThoracic Cancer20196
48Anticancer drug R&D landscape in ChinaJournal of Hematology and Oncology20206
49Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinomaTheranostics20216
50A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphomaOncotarget20166